Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,593

Document Document Title
WO/2022/163335A1
The purpose of the present invention is to provide a photosensitive resin composition and compound having a low dielectric loss tangent when made into a cured film. The present invention is a photosensitive resin composition containing (...  
WO/2022/155273A1
Methods, pharmaceutical formulations, and kits are provided for using Transient Receptor Potential Vanilloid 1 (TRPV1) agonists to increase rectal pressure and induce defecation in mammals.  
WO/2022/133551A1
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...  
WO/2022/106636A1
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...  
WO/2022/106083A1
A process for the production of biuret from urea wherein: a urea aqueous solution (24) withdrawn from the recovery section of a urea plant is processed to remove water and obtain a concentrated urea melt (25); said urea melt is processed...  
WO/2022/102557A1
The present invention relates to: a compound represented by formula (I) (in the formula, X denotes -CH2- or -NH-; R1 and R3 each independently denote a substituted or unsubstituted hydrocarbon group having 5-30 carbon atoms, with any -CH...  
WO/2022/104148A1
Disclosed herein, inter alia, are compounds for inhibiting IREl α and uses thereof.  
WO/2022/089774A1
The invention relates to a process for preparing 1,2'-benzisothiazoline-3-one according to formula (I), comprising the following steps: (a) reacting a 2-halogenbenzonitrile compound of general formula (II) with a reaction mixture, contai...  
WO/2022/078533A1
The present invention relates to substituted 1-phenyl-3-yl-urea derivatives of the general formula (I), and preparations containing these derivatives, (I) wherein Y is nitrogen or carbon; R1 is halogen, methoxy group, methylsulfanyl grou...  
WO/2015/136292A9
The invention relates to a DDX3X inhibitorfor use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention ...  
WO/2022/048922A1
The present invention relates to a compound of the following formula (I) or (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture the...  
WO/2022/034201A1
Bisorthohydroxy aromatic urones and their use as curatives and cure accelerators in resin systems particularly epoxy resin systems provide formulations with good outlife, low curing temperatures and desirable glass transition temperature...  
WO/2022/027122A1
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...  
WO/2022/018450A1
The present invention relates to crystalline forms of vadadustat, including a crystalline vadadustat anhydrate and a crystalline vadadustat urea molecular complex. The present invention also relates to processes for their preparation and...  
WO/2022/003181A1
The present invention relates to urea derivatives of polyene macrolides having the following chemical formula: wherein: - R1 is hydrogen or an alkyl or aryl or acyl group, and R2, independently of R1, is hydrogen or an alkyl or aryl or a...  
WO/2021/260090A1
The invention relates to compounds of Formula (I) wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical com...  
WO/2021/257669A1
The present disclosure includes synthetic methods for preparing certain substituted (hetero)arylmethyl urea compounds, compositions comprising the same, and crystalline forms thereof, which can be used to treat, ameliorate, and/or preven...  
WO/2021/252640A1
The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, interme...  
WO/2021/246485A1
Provided is a carbamate production method characterized by bringing a carbon dioxide-containing mixed gas in which the partial pressure of carbon dioxide is 0.001 atm or greater but less than 1 atm, into contact with an amino group-conta...  
WO/2021/246316A1
The present invention reduces energy derived CO2 through effective use of CO2 that is in exhaust gas from a cement production facility and that is not derived from fossil fuel, by converting CO2 in exhaust gas from a cement production fa...  
WO/2021/230956A1
The present disclosure provides processes and apparatuses for the scaled-up manufacture of lomustine via continuous flow manufacture. Such continuous flow processes may optionally include the crystallization of lomustine and the apparatu...  
WO/2021/226276A2
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...  
WO/2021/219594A1
The invention relates to compounds of Formula (I) wherein X1, X2, X3, Y, R1, R2A, R2B, R3, and R4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions con...  
WO/2021/222789A1
Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.  
WO/2021/214048A1
The invention pertains to a novel structure (I) that provides an activity as a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and 5-lipoxygenase (5-LOX). The invention pertains to multiple derivatives of the new class of d...  
WO/2021/217041A1
Disclosed are N-substituted α-amino and α-hydroxy carboxamides, pharmaceutical compositions comprising them, and methods of using them.  
WO/2021/217040A1
Disclosed are carbamate and urea derivatives, pharmaceutical compositions comprising them, and methods of using them.  
WO/2021/211436A1
The present application provides idebenone derivatives or analogues useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating the disease or disor...  
WO/2021/206132A1
Provided is a method for producing, using a simple procedure, an O-methylisourea sulfate that is important as an intermediate of medicines, agrochemicals and industrial chemicals. The present invention is a method for producing an O-me...  
WO/2021/204175A1
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...  
WO/2021/185391A1
The present invention relates to substituted 1-[2-(hydroxyalkyl)phenyl]-3-yl-urea derivatives of the general formula (I), which inhibit one of the key plant enzymes cytokinin oxidase/dehydrogenase (CKX); wherein R1 is hydrogen, halogen, ...  
WO/2021/185390A1
The present invention relates to substituted 2-(3-phenylureido)benzamide derivatives of the general formula (I), wherein R1 is hydrogen, amino group, (C1 to C5)alkyl, (C2 to C5)alkenyl or (C2 to C5)alkynyl, optionally substituted with hy...  
WO/2021/180655A1
The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascul...  
WO/2021/182457A1
[Problem] To develop novel compounds having an activity of inhibiting the function of Pin1 so as to use these compounds as pharmaceutical candidate compounds. [Solution] A compound represented by formula (I) or a salt thereof, and a Pin1...  
WO/2021/170154A1
Method of purification of carglumic acid, substance formula I, contains the following steps: a) Dissolution of carglumic acid in dimethyl sulfoxide; b) Addition of a precipitation solvent; c) Isolation of the precipitated solvate of carg...  
WO/2021/168561A1
The present invention provides solvent-limited processes for the preparation of an existing crystalline solid form of an active pharmaceutical ingredient comprising mixing, in the presence of solvent vapour, of a solid active pharmaceuti...  
WO/2021/159015A1
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formul...  
WO/2021/142570A1
The present invention provides a method for preparing storage-stable biuret polyisocyanate. The biuret polyisocyanate product obtained by using the method of the present invention has excellent monomer content storage stability, i.e. lit...  
WO/2021/119108A1
The present invention describes methods for treating idiopathic short stature. Described herein are also methods of increasing a subject's height. The methods involve administering an effective amount of a pan FGFR inhibitor or a selecti...  
WO/2021/098671A1
Disclosed is an ureido-containing benzimidazole derivative, wherein the general structural formula is as shown in formula (I). Also disclosed are a method for preparing the compound and the use thereof in the preparation of anti-chronic ...  
WO/2021/102266A1
Di alkenyl succinic amide acids and processes for making and using same. The di alkenyl succinic amide acid can have a chemical formula of (I): where R1 and R2 can independently be a linear or branched C8 to C24 alkenyl group, Z1, Z2, Z3...  
WO/2021/080352A1
The present invention relates to: a derivative in which glutamate-urea-Lysine (GUL) and isonitril are linked by a linker; a radioisotope labeled compound comprising the derivative; and a pharmaceutical composition for treating and diagno...  
WO/2021/056665A1
Disclosed in the present invention are a gemini surfactant for oil displacement, and a preparation method for and an application of the gemini surfactant. The gemini surfactant is 1,3-dialkyl-1,3-dipolyoxyethylene ether urea or 1,3-dialk...  
WO/2021/038490A1
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 ...  
WO/2021/027237A1
The present invention relates to a method for preparing a supercritical carbon dioxide thickener for the exploitation of tight oil and gas reservoirs. The method can solve the problem of oil and gas deposits being damaged as a result of ...  
WO/2021/020429A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.  
WO/2021/008908A1
The invention relates to a method for producing polyisocyanates having a low monomer content, said method comprising the following steps: (i) modifying at least one monomeric diisocyanate to obtain a mixture containing at least one polyi...  
WO/2020/264176A1
Heteroaryl and aliphatic analogs of diarylurea-based cannabinoid 1 receptor (CB1 R) allosteric modulators of formula (I) are described. Exemplary analogs can provide improved potencies and pharmacokinetic properties. Methods of using the...  
WO/2020/252240A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2020/210909A1
This application relates to compounds of Formula I. R1a, R1b and R1c is –CO2H, –SO2H, –SO3H, –SO4H, –PO2H, –PO3H or –PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g.–O–, –S–, -S(O)-, S(O)2-, –NHC(O)–, ...  

Matches 1 - 50 out of 4,593